Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4031 - FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM): final results of the FFCD 1102 phase II trial.


09 Sep 2017


Poster display session


Cytotoxic Therapy;  Colon and Rectal Cancer


Jean-Baptiste BACHET


Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393


J. BACHET1, O. Lucidarme2, C.B. Levache3, E. Maillard4, J.L. Raoul5, T. Lecomte6, C. Desauw7, F. Brocard8, S. Pernot9, G. Breysacher10, J. Lagasse11, F. Di Fiore12, P.L. Etienne13, O. Dupuis14, A. Aleba15, C. Lepage16, J. Taieb17

Author affiliations

  • 1 Gastroenterology And Digestive Oncology, Groupe Hospitalier Pitié Salpetriere, 75651 - Paris/FR
  • 2 Radiology, Groupe Hospitalier Pitié Salpetriere, 75651 - Paris/FR
  • 3 Digestive Oncology, Clinique Francheville, 24000 - Périgueux/FR
  • 4 Biostatistics, FFCD-, 21079 - Dijon/FR
  • 5 Medical Oncology, Institute Paoli Calmettes, 13274 - Marseille/FR
  • 6 Department Of Gastroenterology, CHU de Tours, Hôpital Trousseau, 37170 - Chambray-lès-Tours/FR
  • 7 Medical Oncology, C.H.U. Claude Huriez, 59037 - Lille/FR
  • 8 Medical Oncology, Polyclinique de Gentilly, 54000 - Nancy/FR
  • 9 Digestive Oncology, Hôpital européen Georges-Pompidou, 75015 - Paris/FR
  • 10 Gastroenterolgy, CH Pasteur, 68024 - Colmar/FR
  • 11 Gastroenterology And Digestive Oncology, CH Orleans, 45100 - Orleans/FR
  • 12 Department Of Oncology, CHU Charles Nicolle, 76031 - Rouen/FR
  • 13 Digestive Oncology, Clinique Armoricaine de Radiologie, 22000 - St. Brieuc/FR
  • 14 Medical Oncology, Clinique Victor Hugo, 72000 - Le Mans/FR
  • 15 Digestive Oncology, CH General (Niort), 79021 - Niort/FR
  • 16 Gastroenterology, CHU Le Bocage, FFCD, Burgundy University, INSERM U866, 21079 - Dijon/FR
  • 17 Department Of Gastroenterology And Digestive Oncology, Hôpital Européen Georges Pompidou, Paris/FR


Abstract 4031


Optimal therapeutic strategy in patients (pts) with RCSM remains discussed and many front-line options can be discussed to best treat primary tumor and metastatic disease: surgery (S), radiotherapy (RT), chemoradiotherapy (CRT) or chemotherapy (CT). The FFCD 1102 trial evaluated the efficacy of upfront FOLFIRINOX in this setting.


Chemotherapy-naïve pts with RCSM received FOLFIRINOX: oxaliplatin 85 mg/m2 d1 + irinotecan 180 mg/m2 D1 + leucovorin 400 mg/m2 d1 followed by 5FU 400 mg/m2 bolus d1 and 2,400 mg/m2 46h continuous infusion biweekly; 8 cycles were mandatory. CT-scan and MRI at baseline, 2 and 4 months (m) were centrally reviewed. The objective responses were assessed on CT-scan for metastases (RECIST criteria) and MRI for rectal tumor (volume decrease ≥ 70%). The primary endpoint was disease control rate at 4 m (4m DC). With a Simon 2-stage design, a targeted (H1) 4m DC > 75% was defined (unilateral alpha of 5% and statistical power of 90%).


65 pts were enrolled (07/2012 to 02/2015): male 78%; median age 61 years; PS 0-1 99%; liver metastases 92%; ³2 metastatic sites 63%. All pts received at least 1 cycle of CT, and 85% the 8 planned cycles. The 4m DC was 94% (95% CI, 86.3-97.8). Percentages of patients with local symptoms (rectal bleeding, rectal syndrome, sub-occlusion) were 72%, 16% and 10% at baseline, 2 and 4 m, respectively. For evaluable pts at 4 m, response rates of metastases and primary tumor were 86% (55/64) and 62.5% (30/48). Median follow-up was 35.0 m (95% CI, 31.3-43.7). After 8 cycles of FOLFIRINOX, therapeutic strategy was investigators’ choice: 60 pts (92%) received CT, 38 (58%) had a RT or CRT, 32 (49%) a rectal tumor resection (RS), and 22 (34%) a surgery and/or ablation of their metastases (MS). On ITT, median PFS and OS were 10.9 m (95% CI, 8.8-12.9) and 33.4 m (95% CI, 22.6-38.2), respectively. OS were 17.6 m (95% CI, 11.8-26.4) in 28 pts (43%) who had no surgery, 38.8 m (95% CI, 13.6-44.6) in 15 pts (23%) who had RS only, and 42.1 m [33.45-NA] in 22 pts who had MS.


Front-line FOLFIRINOX allows a good local and distant control of RCSM, and leaves the opportunity to decide best therapeutic strategy according to the response obtained after the induction step.

Clinical trial identification


Legal entity responsible for the study

FFCD (Fédération Francophone de Cancérologie Digestive)


FFCD (Fédération Francophone de Cancérologie Digestive)


J-B. Bachet: Honoraria: Bayer, Celgene, Sanofi; consulting or advisory role: Amgen, Bayer, Merck Serono, Servier; travel, accommodations: Celgene, Merck Serono. O. Lucidarme: Consulting or advisory role: Boehringer-Ingelheim; travel, accomodations: Bracco Diagnostics. C.B. Levache: Honoraria: Amgen, Roche/Genentech; consulting or advisory role: Amgen, Roche/Genentech; travel, accommodations: Amgen, Roche/Genentech. J.L. Raoul: Honoraria: Celgene, Merck Serono; consulting or advisory role: Bayer, BTG, Taiho Pharmaceutical; research funding: Celgene. S. Pernot: Honoraria: Amgen. J-P. Lagasse: Expert testimony: Sanofi; travel, accommodations: Ipsen, Merck Serono, Novartis. F. Di Fiore: Honoraria: Amgen, Merck Serono, Roche/Genentech, Sanofi. C. Lepage: Travel, accommodations: Ipsen. J. Taieb: Honoraria: Amgen, Celgene, Lilly, Merck Serono, Roche/Genentech; travel, accommodations: Amgen, Celgene, Merck Serono, Roche/Genentech. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.